# US 2016/0354477 A1 · Conjugates of tumor necrosis factor inhibitors to functionalized polymers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354477 A1
- Document ID: US20160354477A1
- Status: Published application
- Kind: A1
- Application number: 14/980,322
- Filed: 2015-12-28
- Published: 2016-12-08
- Earliest claimed: 2012-06-12
- Assignees: QuiaPEG Pharmaceuticals AB
- Applicants: QuiaPEG Pharmaceuticals AB
- Inventors: Marek Kwiatkowski
- Web page: https://patentgrep.com/patent/US20160354477A1

## CPC

- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61K 38/1816: {Erythropoietin [EPO]}
- A61K 38/28: Insulins
- A61K 38/36: Blood coagulation or fibrinolysis factors
- A61K 38/37: Factors VIII
- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61K 38/4846: {Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)}
- A61K 38/4866: {Protein C (3.4.21.69)}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 39/39566: {against immunoglobulins, e.g. anti-idiotypic antibodies}
- A61K 47/68: the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61P 11/06: Antiasthmatics
- C07K 1/1077: {by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids}
- C07K 14/62: Insulins
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/4291: {against IgE}
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- C12N 9/2462: {Lysozyme (3.2.1.17)}
- C12N 9/96: Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- C12Y 302/01017: Lysozyme (3.2.1.17)
- A61K 2039/505: {comprising antibodies}
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

This document relates to conjugates of TNF inhibitors or derivatives thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.

## Claims

### Claim 1

(canceled)

### Claim 2

A method of making a TNF inhibitor conjugate, said method comprising reacting a TNF inhibitor with a preparation comprising a water-soluble, non-peptidic, and non-nucleotidic polymer backbone having at least one terminus covalently bonded to a structure of formula (1) under conditions suitable for group M or R to react with a TNF inhibitor:
or a salt thereof,
wherein:
A is the point of covalent bonding to the terminus of the polymer backbone;
E is O;
P is phosphorous;
K is selected from the group consisting of: alkylene, alkyleneoxyalkylene, and oligomeric alkyleneoxyalkylene;
G is selected from the group consisting of: hydrogen, alkoxy, and a hydrophobic separation handle;
Z1 and Z2 are O;
L is selected from the group consisting of: a divalent radical of a nucleoside, alkylene, alkyleneoxyalkylene, oligomeric alkyleneoxyalkylene, and unsubstituted and substituted arylene;
M is a protected group that when deprotected is reactive with a TNF inhibitor or is a group reactive with a TNF inhibitor;
R is absent or selected from the group consisting of: hydrogen, a protecting group, a hydrophobic separation handle, or an activating group;
R1 is absent or a hydrophobic separation handle;
wherein when M is a protected group that when deprotected is reactive with a a TNF inhibitor, then R is a protecting group or a hydrophobic separation handle;
wherein when M is a group reactive with a TNF inhibitor, R is absent, hydrogen, or an activating group; and
wherein only one of R, R1, and G can be a hydrophobic separation handle.

### Claim 3 (depends on 2)

The method of claim 2, wherein the polymer has from 2 to 100 termini.

### Claim 4 (depends on 2)

The method of claim 2, wherein only one termini of the polymer backbone is covalently bonded to the structure of formula (1).

### Claim 5 (depends on 2)

The method of claim 2, wherein the polymer backbone has two termini.

### Claim 6 (depends on 5)

The method of claim 5, wherein only one termini of the polymer backbone is covalently bonded to the structure of formula (1).

### Claim 7 (depends on 5)

The method of claim 5, wherein both termini of the polymer backbone are covalently bonded to the structure of formula (1).

### Claim 8 (depends on 2)

The method of claim 2, wherein said group reactive with a TNF inhibitor is selected from the group consisting of: hydroxyl, amine, thiol, carboxyl, aldehyde, glyoxal, dione, alkenyl, alkynyl, alkedienyl, azide, acrylamide, vinyl sulfone, hydrazide, aminoxy, maleimide, dithiopyridine, iodoacetamide.

### Claim 9 (depends on 2)

The method of claim 2, wherein K is selected from the group consisting of:
methylene, ethylene, propylene, isopropylene, butylene, isobutylene, sec-butylene, tert-butylene, and hexylene, or a residue from diethylene glycol, triethylene glycol, tetraethylene glycol or hexaethylene glycol.

### Claim 10 (depends on 2)

The method of claim 2, wherein G is a substituted or unsubstituted trityloxy.

### Claim 11 (depends on 2)

The method of claim 2, wherein L is a substituted or unsubstituted C1-C12 alkylene.

### Claim 12 (depends on 2)

The method claim 2, wherein R is selected from the group consisting of: trityl, monoalkoxytrityl, dialkoxytrityl, pixyl, alkoxypixyl, fluorenylmethyloxycarbonyl, trifluoroacetyl, acetal, and cyclic acetal.

### Claim 13 (depends on 2)

The method of claim 2, wherein said group reactive with a TNF inhibitor is carboxyl and R is absent or selected from the group consisting of: N-hydroxysuccinimidyl, p-nitrophenyl, or pentachlorophenyl.

### Claim 14 (depends on 2)

The method of claim 2, wherein said polymer backbone is selected from the group consisting of poly(alkylene glycol), poly(oxyethylated polyol), poly(olefinic alcohol), poly(α-hydroxy acid), poly(vinyl alcohol), polyoxazoline, and copolymers.

### Claim 15 (depends on 2)

The method of claim 2, wherein said polymer backbone is poly(ethylene glycol).

### Claim 16 (depends on 15)

The method of claim 15, wherein said poly(ethylene glycol) has an average molecular weight from about 500 Da to about 100,000 Da.

### Claim 17 (depends on 2)

The method of claim 2, wherein said preparation comprises at least 50% by weight of said water-soluble, non-peptidic, and non-nucleotidic polymer backbone having at least one terminus covalently bonded to a structure of formula (1).

### Claim 18 (depends on 17)

The method of claim 17, wherein said preparation comprises at least 98% by weight of said water-soluble, non-peptidic, and non-nucleotidic polymer backbone having at least one terminus covalently bonded to a structure of formula (1).

### Claim 19 (depends on 2)

The method of claim 2, said method further comprising (i) removing the hydrophobic separation handle(s) from said structure of formula (1) and (ii) optionally reacting the compound obtained in step (i) with an activating agent before reacting with a TNF inhibitor.

### Claim 20 (depends on 2)

The method of claim 2, said method further comprising removing the hydrophobic separation handle(s) from said structure of formula (1) after reacting with a TNF inhibitor.

### Claim 21

A conjugate, or a pharmaceutically acceptable salt thereof, comprising a water-soluble, non-peptidic, and non-nucleotidic polymer backbone having at least one terminus covalently bonded to a structure of formula (9):
or a salt thereof,
wherein:
A is the point of covalent bonding to the terminus of the polymer backbone;
E is O;
P is phosphorous;
K is selected from the group consisting of: alkylene, alkyleneoxyalkylene, and oligomeric alkyleneoxyalkylene;
G is selected from the group consisting of: hydrogen, alkoxy, and a hydrophobic separation handle;
Z1 and Z2 are O;
L is selected from the group consisting of: a divalent radical of a nucleoside, alkylene, alkyleneoxyalkylene, oligomeric alkyleneoxyalkylene, and unsubstituted and substituted arylene;
R1 is absent or a hydrophobic separation handle, wherein only one of R1 and G can be a hydrophobic separation handle;
L2 is a covalent linking moiety between L and B; and
B is a TNF inhibitor.

### Claim 22 (depends on 21)

The conjugate of claim 21, wherein the polymer has from 2 to 100 termini.

### Claim 23 (depends on 21)

The conjugate of claim 21, wherein only one termini of the polymer backbone is covalently bonded to the structure of formula (1).

### Claim 24 (depends on 21)

The conjugate of claim 21, wherein the polymer backbone has two termini.

### Claim 25 (depends on 24)

The conjugate of claim 24, wherein only one termini of the polymer backbone is covalently bonded to the structure of formula (1).

### Claim 26 (depends on 24)

The conjugate of claim 24, wherein both termini of the polymer backbone are covalently bonded to the structure of formula (1).

### Claim 27 (depends on 21)

The conjugate of claim 21, wherein said group reactive with a TNF inhibitor is selected from the group consisting of: hydroxyl, amine, thiol, carboxyl, aldehyde, glyoxal, dione, alkenyl, alkynyl, alkedienyl, azide, acrylamide, vinyl sulfone, hydrazide, aminoxy, maleimide, dithiopyridine, iodoacetamide.

### Claim 28 (depends on 21)

The conjugate of claim 21, wherein K is selected from the group consisting of: methylene, ethylene, propylene, isopropylene, butylene, isobutylene, sec-butylene, tert-butylene, and hexylene, or a residue from diethylene glycol, triethylene glycol, tetraethylene glycol or hexaethylene glycol.

### Claim 29 (depends on 21)

The conjugate of claim 21, wherein G is a substituted or unsubstituted trityloxy.

### Claim 30 (depends on 21)

The conjugate of claim 21, wherein L is a substituted or unsubstituted C1-C12 alkylene.

### Claim 31 (depends on 21)

The conjugate claim 21, wherein R is selected from the group consisting of: trityl, monoalkoxytrityl, dialkoxytrityl, pixyl, alkoxypixyl, fluorenylmethyloxycarbonyl, trifluoroacetyl, acetal, and cyclic acetal.

### Claim 32 (depends on 21)

The conjugate of claim 21, wherein said group reactive with a TNF inhibitor is carboxyl and R is absent or selected from the group consisting of: N-hydroxysuccinimidyl, p-nitrophenyl, or pentachlorophenyl.

### Claim 33 (depends on 21)

The conjugate of claim 21, wherein said polymer backbone is selected from the group consisting of poly(alkylene glycol), poly(oxyethylated polyol), poly(olefinic alcohol), poly(α-hydroxy acid), poly(vinyl alcohol), polyoxazoline, and copolymers.

### Claim 34 (depends on 21)

The conjugate of claim 21, wherein said polymer backbone is poly(ethylene glycol).

### Claim 35 (depends on 34)

The conjugate of claim 34, wherein said poly(ethylene glycol) has an average molecular weight from about 500 Da to about 100,000 Da.
